This publication by UNAIDS, UNDP and the International Organisation for Migration examines various dimensions related to migration and HIV and AIDS.
The context of the Ebola epidemic presented extreme challenges for Oxfam, as it did for many organisations. At the onset of the epidemic, there was a general lack of understanding of the disease and how to respond to it effectively and safely. A pervasive and persistent climate of fear, coupled with... changing predictions about the likely evolution of the epidemic, influenced analysis and response at all levels. There was strong pressure to treat the epidemic as a medical emergency requiring a medical response – organised through topdown processes – rather than standard humanitarian coordination
more
UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
Regional Operational Plan 2016 FY17 Strategic Direction Summary
2 May 2016
Cochrane Database Syst Rev. 2016 Jul 1; (6): 1–61 -Published online 2016 July 1
How we respond both now and going forward will help mitigate the impact of COVID-19, and to the extent possible preserve children’s rights to Survive, Learn, and Be Protected. We will focus our efforts on the most critical work essential to maintaining these commitments to the extent possible.
This document will be continuously updated. Version as of April 27th, 2020
Migrant and displaced children are at heightened risk to the immediate and secondary impacts of COVID-19. They often live in cramped conditions with limited access to water, sanitation, and hygiene (WASH), may be in immig...ration detention or “left behind,” live with disabilities, unaccompanied or separated from their families, and can be hardest to reach with accurate information in a language they understand. Migrant workers and refugees can live in the most disadvantaged urban areas, where access to essential services is already limited. Refugee and migrant children may also be prevented from accessing essential services due to legal, documentation, linguistic or safety barriers. Further, the misinformation on the spread of COVID-19 exacerbates the xenophobia and discrimination that migrant and displaced children and their families already face.
more
.This assessment was conducted using focus group discussion(FGD)with peopleliving with disabilities who were members of the Ethiopian National Association of the Deaf(Person with hearing impairment), Ethiopian National Association of the Deaf -Blind ( Person with hearing and visual impairment), Ethi...opian National Association of the Blind (Person with visual impairment), Ethiopian National Association of the Physically Handicapped (Person with physical impairment), Ethiopian National Association of Intellectual Disability (Person with intellectual disability). In total 152 people living with disabilities participated in the discussion groups.Results from the assessment were analysed based on themes and are presented by each group in the following report.
more
March 9, 2021
Here you can find a collection of useful manuals, videos, infographics and resource platforms.
The category "Vaccine hesitancy & myths" will be updated regularly with new documents, videos and information material. Please check this category within the COVID-19
https://medbox.org/fi...lter/602505261716D/toolbox/vaccination-strategy#GO
more
Available in different languages
A short wordless story, that will help people to understand what to do if you have Coronavirus and how to keep yourself and those who you care about safe. The story also shows how to safely help others who may be self-isolating. Supplementary text at the end of the story gives information on where p...eople can seek help if they are unwell and signposts to other useful resources
more
A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to
Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease patterns in southern countries of East Africa to an increase in virulence towards the north. However, only limited d...ata on the clinical presentation of T.b. rhodesiense HAT is available. From 2006-2009 we conducted the first clinical trial program (I MPAMEL III) in T.b. rhodesiense endemic areas of
Tanzania and Uganda in accordance with international standards (ICH-GCP). The primary and secondary outcome measures were safety and efficacy of an abridged melarsoprol schedule for treatment of second stage disease. Based on diagnostic findings and clinical examinations at baseline we describe the clinical presentation of T.b. rhodesiense HAT in second stage patients from two distinct geographical settings in East Africa.
more